IPHA Stock — Innate Pharma SA

Up next

Next earnings call

Dec 30, 2026 Est · unconfirmed · in 6 wks

Q3 2026 earnings call transcript

call held Nov 5, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 12

Current report 6-K

Current report AI summary on its way

Nov 10

Investor event

IPH4502 dose-finding data readout due next week

Innate Pharma plans to present IPH4502 dose-finding data next week from 76 patients across over 10 tumor types.

6 source passages

So a little bit about Innate Pharma. So our lead ADC is IPH4502. We have a big data readout coming next week on the 18th of November. which we'll be presenting at the triple meeting. We basically have completed the enrollment in the dose-finding study. We have 76 patients, as you mentioned. This is a basket study tumor approach, so there are over 10 different tumor types in the study across a range of different doses. Open the document at this passage

Nov 5

Earnings call

Phase 3 begun as cash reaches 96.8 million

Innate Pharma initiated lacutamab’s TELEMAC3 Phase 3 study and received SOBI’s $75 million upfront payment. Cash reached 96.8 million; IPH4502 Phase 1 data are due November 18, 2026, and monalizumab’s PACIFIC 9 readout in the first half of 2027.

6 source passages

The partnership is now effective, and the $75 million upfront payment has been received. Financially, our cash position as of September 30th, 2026 was 96.8 million. For IPH 4502, we will present Phase 1 data at the EORTC NCI AACR Symposium on November 18, 2026. Turning to Monolizumab, the Pacific 9 phase 3 study led by AstraZeneca is now expected to read out in the first half of 2027. TELEMAC3, our confirmatory phase 3 study in CTCL, has been initiated, with the first patient expected in the first quarter of 2027. Under the terms of the agreement, we received $75 million upfront payment Open the document at this passage

Nov 5

Current report 6-K

€96.8 million cash and key 2027 pipeline milestones

Innate Pharma reported €96.8 million cash as of September 30, 2026, funding operations until the end of Q1 2028. IPH4502 Phase 1 data are due November 18, 2026, and lacutamab dosing is expected in Q1 2027.

4 source passages

Cash position of €96.8 million1 as of September 30, 2026; anticipated cash horizon until the end of Q1 2028 Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event Phase 1 dose-escalation data will be presented as a poster at the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, on November 18, 2026 (Barcelona). Following closing of the transaction, Innate is advancing TELLOMAK-3, the confirmatory Phase 3 study of lacutamab in Cutaneous T Cell Lymphoma (CTCL), with first patient dosing expected in Q1 2027. Open the document at this passage

Oct 27

Current report 6-K

Current report

Innate Pharma SA said AstraZeneca updated the expected high-level PACIFIC-9 Phase 3 trial data readout to the first half of 2027 from the second half of 2026, reflecting the study’s event-driven nature.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$11.44M

Trailing 12 months

Net income (TTM)

−$55.36M

Trailing 12 months

Revenue growth YoY

-55.2%

Year over year

Operating margin

-485.2%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-32.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+11.8%

Year over year · more shares

Price change (1Y)

-24.2%

Trailing year

Short interest

0.1%

Latest settlement · 8.9 days to cover

View all 125 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −19%

below

Price vs 50-day avg −15%

below

RSI (14) 41

neutral

MACD trend Positive

52-week position 15%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −4%

trailing

6-month return −20%

trailing

YTD return −21%

this year

Relative strength −20%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $2 › 200d $2 — 200d above 50d

Institutional flow Accumulating

10 of 10 funds reported for Sep 30 · net +7.0K sh shares · +3 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.11% of shares out · ▼ -2.9% MoM · 8.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

10 holders — mid 3-yr range

Squeeze score 38

low risk · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 95%

annualized · 1-yr

Max drawdown −48%

past year

ATR 7.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−19% Bearish

Price vs 50-day avg

−15% Bearish

RSI (14)

41 Neutral

MACD trend

Positive Bullish

52-week position

15% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $2 › 200d $2 — 200d above 50d

Institutional flow Accumulating

10 of 10 funds reported for Sep 30 · net +7.0K sh shares · +3 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.11% of shares out · ▼ -2.9% MoM · 8.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

10 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $1 · 15% Range high $3

vs 200-day avg -19% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
IPHA Innate Pharma SA this stock	$154.15M	-21.1%	—	—	0.1%
VRTX Vertex Pharmaceuticals Inc	$136.56B	+18.8%	+46.2%	34.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$98.84B	+23.8%	+20.8%	21.1	2.1%
MRNA Moderna, Inc.	$90.38B	+657.4%	+4.3%	—	8.2%
CSLLY Csl Ltd	$66.05B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

12

% held: 0.2%
Reported: 10 of 10
Top holder: Lion Point Capital, LP

Held Float

View

Held by Funds

Fund positions

1

View

Short & Settlement

Short Interest Falling

Shares short

123.2K

Days to cover: 8.9d
Change: -3.6K sh

View

Short Volume

Short vol %

52%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

84

Value: $123
As of: Oct 14, 2026

View

Off-Exchange

Off-exchange %

61.7%

Week of: Oct 5, 2026

Off-exch Lit

View

Filings

SEC Filings

Latest

6-K

Filed: Nov 12, 2026
This year: 34

View

Earnings & Events

Webcasts

Last webcast

Nov 10, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
IPHA	-4.2%	-3.5%	-19.8%	-5.5%	-21.1%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	-6.8%	-2.3%	-20.3%	-5.3%	-31.8%

IPHA · Innate Pharma SA

Price & Indicators

Up next

Latest documents

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance